16-177340-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PP3_StrongPP5_Very_Strong
The ENST00000320868.9(HBA1):c.358C>T(p.Pro120Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000031 in 1,613,180 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000039 ( 1 hom., cov: 32)
Exomes 𝑓: 0.000030 ( 1 hom. )
Consequence
HBA1
ENST00000320868.9 missense
ENST00000320868.9 missense
Scores
7
6
5
Clinical Significance
Conservation
PhyloP100: 3.35
Genes affected
HBA1 (HGNC:4823): (hemoglobin subunit alpha 1) The human alpha globin gene cluster located on chromosome 16 spans about 30 kb and includes seven loci: 5'- zeta - pseudozeta - mu - pseudoalpha-1 - alpha-2 - alpha-1 - theta - 3'. The alpha-2 (HBA2) and alpha-1 (HBA1) coding sequences are identical. These genes differ slightly over the 5' untranslated regions and the introns, but they differ significantly over the 3' untranslated regions. Two alpha chains plus two beta chains constitute HbA, which in normal adult life comprises about 97% of the total hemoglobin; alpha chains combine with delta chains to constitute HbA-2, which with HbF (fetal hemoglobin) makes up the remaining 3% of adult hemoglobin. Alpha thalassemias result from deletions of each of the alpha genes as well as deletions of both HBA2 and HBA1; some nondeletion alpha thalassemias have also been reported. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.972
PP5
Variant 16-177340-C-T is Pathogenic according to our data. Variant chr16-177340-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 811900.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HBA1 | NM_000558.5 | c.358C>T | p.Pro120Ser | missense_variant | 3/3 | ENST00000320868.9 | NP_000549.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HBA1 | ENST00000320868.9 | c.358C>T | p.Pro120Ser | missense_variant | 3/3 | 1 | NM_000558.5 | ENSP00000322421 | P1 | |
HBA1 | ENST00000472694.1 | n.494C>T | non_coding_transcript_exon_variant | 2/2 | 1 | |||||
ENST00000702457.1 | n.151G>A | non_coding_transcript_exon_variant | 1/1 | |||||||
HBA1 | ENST00000397797.1 | c.262C>T | p.Pro88Ser | missense_variant | 3/3 | 2 | ENSP00000380899 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152202Hom.: 1 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
152202
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000566 AC: 14AN: 247332Hom.: 0 AF XY: 0.0000447 AC XY: 6AN XY: 134312
GnomAD3 exomes
AF:
AC:
14
AN:
247332
Hom.:
AF XY:
AC XY:
6
AN XY:
134312
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000301 AC: 44AN: 1460978Hom.: 1 Cov.: 32 AF XY: 0.0000275 AC XY: 20AN XY: 726802
GnomAD4 exome
AF:
AC:
44
AN:
1460978
Hom.:
Cov.:
32
AF XY:
AC XY:
20
AN XY:
726802
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152202Hom.: 1 Cov.: 32 AF XY: 0.0000672 AC XY: 5AN XY: 74352
GnomAD4 genome
AF:
AC:
6
AN:
152202
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74352
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
4
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
alpha Thalassemia Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Zotz-Klimas Genetics Lab, MVZ Zotz Klimas | Oct 09, 2023 | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | May 20, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 22, 2022 | Variant summary: HBA1 c.358C>T (p.Pro120Ser) results in a non-conservative amino acid change located in the Globin domain (IPR000971) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.7e-05 in 247332 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in HBA1 causing Alpha Thalassemia (5.7e-05 vs 0.0056), allowing no conclusion about variant significance. c.358C>T has been reported in the literature in multiple compound heterozygous and homozygous individuals affected with Alpha Thalassemia (e.g. Giordano_2007, Zanella-Cleon_2008, Joly_2014). These data indicate that the variant is very likely to be associated with disease. In vitro binding assays indicate that while the variant protein is capable of forming dimers, it does not interact with alpha hemoglobin stabilizing proteins or beta subunits, leading to destabilization and increased proteolytic degredation (Yu_2009). Four ClinVar submitters have assessed the variant since 2014: two classified the variant as likely pathogenic, and two as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 23, 2023 | The HBA1 c.358C>T; p.Pro120Ser variant (Hb Groene Hart, also known as Pro119Ser when numbered from the mature protein, rs63750751, HbVar ID: 1123) has been described in the compound heterozygous or homozygous state in individuals affected with alpha thalassemia, and in the heterozygous state in individuals with microcytosis and hypochromia (see link to HbVar, Giordano 2007, Harteveld 2002, Joly 2014, Yu 2009, Zanella-Cleon 2008). This variant is found in the general population with an overall allele frequency of 0.0057% (16/278694 alleles) in the Genome Aggregation Database. Functional studies of the variant protein demonstrate impaired binding to alpha hemoglobin stabilizing protein and beta globin, leading to destabilization and increased proteolytic degradation (Yu 2009). Based on available information, this variant is considered pathogenic. REFERENCES Link to HbVar: https://globin.bx.psu.edu/hbvar/menu.html Giordano P et al. The first case of Hb Groene Hart (alpha119(H2)Pro-->Ser, CCT-->TCT (alpha1)) homozygosity confirms that a thalassemia phenotype is associated with this abnormal hemoglobin variant. Hemoglobin. 2007;31(2):179-82. PMID: 17486500. Harteveld C et al. Hb Groene Hart: a new Pro-->Ser amino acid substitution at position 119 of the alpha1-globin chain is associated with a mild alpha-thalassemia phenotype. Hemoglobin. 2002 Aug;26(3):255-60. PMID: 12403490. Joly P et al. Description of the phenotypes of 63 heterozygous, homozygous and compound heterozygous patients carrying the Hb Groene Hart (alpha119(H2)Pro->Ser; HBA1: c.358C>T) variant. Hemoglobin. 2014;38(1):64-6. PMID: 24111644. Yu X et al. Analysis of human alpha globin gene mutations that impair binding to the alpha hemoglobin stabilizing protein. Blood. 2009 Jun 4;113(23):5961-9. PMID: 19349619. Zanella-Cleon I et al. Detection of a thalassemic alpha-chain variant (Hemoglobin Groene Hart) by reversed-phase liquid chromatography. Clin Chem. 2008 Jun;54(6):1053-9. PMID: 18420733. - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Oct 22, 2019 | The best available variant frequency is uninformative because it is below the disease allele frequency. Found in at least one patient with expected phenotype for this gene. Conflicting predictions of the effect on the protein. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Assessment of experimental evidence suggests this variant results in abnormal protein function. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 11, 2022 | Also reported as Hb Groene Hart [119(H2)Pro>Ser (1); HBA1: c.358C>T]; Observed in the heterozygous state in alpha thalassemia carriers or patients with mild phenotypes (Giambona A et al., 2008; Cardiero G et al., 2020); Published functional studies demonstrate a damaging effect on the interaction with alpha hemoglobin stabilizing protein and the beta subunit (Yu X et al., 2009; Wajcman H et al., 2011); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 21950764, 12403490, 25130136, 18603555, 23806011, 17486500, 19349619, 24111644, 32751969, 31553106, 26485748) - |
HBA1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 25, 2024 | The HBA1 c.358C>T variant is predicted to result in the amino acid substitution p.Pro120Ser. This variant is also referred to as p.Pro119Ser or Hb Groene Hart. This variant has been reported in the heterozygous state in a father and son with microcytic hypochromic anemia (Harteveld et al. 2002. PubMed ID: 12403490) and in the homozygous state and in the heterozygous state along with an -α3.7 deletion in patients with alpha thalassemia (Joly et al. 2013. PubMed ID: 24111644; Giordano et al. 2007. PubMed ID: 174865000). This variant is reported in 0.020% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic. - |
alpha Thalassemia;C0700299:Heinz body anemia;C3161174:Hemoglobin H disease;C4693798:Methemoglobinemia, alpha type;C4693823:Erythrocytosis, familial, 7 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 20, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Benign
DEOGEN2
Uncertain
D;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Uncertain
D
MutationTaster
Benign
D;D
PrimateAI
Benign
T
PROVEAN
Pathogenic
D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D
Sift4G
Uncertain
D;D
Vest4
MutPred
Loss of phosphorylation at T119 (P = 0.1015);.;
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at